Recent Developments of Coagulation Factor Products for Hemophilia Treatment
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: closed (30 July 2022) | Viewed by 6308
Special Issue Editor
Interests: thrombosis; hemophilia; drug discovery and design
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hemophilia management first started in the 1970s upon the introduction of plasma-derived concentrates of coagulation factor VIII and factor IX, which provided effective treatment of the bleeding episodes in patients with hemophilia A and B, respectively. During 1990s, the management of hemophilia was transformed from treating bleeding events using plasma concentrates to prophylactically preventing them by using recombinant coagulation factors. Importantly, the last decade has witnessed further progress toward better therapeutic interventions for hemophilia as represented by the introduction of extended half-life recombinant coagulation factors (Fc-fused FIX eftrenonacog alfa and Fc-fused FVIII efmoroctocog alfa among others). Despite such progress, certain needs remained unmet. Particularly, hemophilia patients with FVIII inhibitors are not good candidates for prophylaxis. Therefore, non-factor therapeutic interventions were developed. Some of those interventions are already approved, such as emicizumab, while others are in advanced clinical development. Emicizumab is a bispecific monoclonal antibody that facilitates interactions between factor IXa and factor X; thus, it promotes thrombin generation by mimicking factor VIIIa activity irrespective of factor VIII deficiency or the presence of its inhibitors. With this breakthrough in the way that different types of hemophilia are being treated, the horizon for new breakthrough interventions appears to be more promising.
This Special Issue titled “Recent Development of Therapeutics for Hemophilia Treatment” invites authors to contribute reviews or original research articles dedicated to the most recent advances on therapeutics for hemophilia treatment. The contributions include the discovery of new therapeutic entities, as well as their assessment in the context of hemophilia. Studies concerning the elucidation of mechanisms of action of new therapeutics are also welcomed.
Dr. Rami A. Al-Horani
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
